BRPI0411985A - tratamento da disfunção sexual - Google Patents

tratamento da disfunção sexual

Info

Publication number
BRPI0411985A
BRPI0411985A BRPI0411985-1A BRPI0411985A BRPI0411985A BR PI0411985 A BRPI0411985 A BR PI0411985A BR PI0411985 A BRPI0411985 A BR PI0411985A BR PI0411985 A BRPI0411985 A BR PI0411985A
Authority
BR
Brazil
Prior art keywords
treatment
sexual dysfunction
sexual
dysfunction
disorder
Prior art date
Application number
BRPI0411985-1A
Other languages
English (en)
Inventor
Alasdair Mark Naylor
Pieter Hadewijn Van Der Graaf
Christopher Peter Wayman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0316673A external-priority patent/GB0316673D0/en
Priority claimed from GB0318095A external-priority patent/GB0318095D0/en
Priority claimed from GB0321308A external-priority patent/GB0321308D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0411985A publication Critical patent/BRPI0411985A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TRATAMENTO DA DISFUNçãO SEXUAL". A presente invenção refere-se com a utilização de inibidores de guanosina-3<39>,5<39>-monofosfato cíclico-fosfodiesterase de tipo cinco (PDE5), associados a agonistas de 5HT1a para o tratamento de disfunção sexual, em particular do distúrbio da excitação sexual feminina (FSAD) com distúrbio do desejo sexual hipoativo (HSDD) concomitante.
BRPI0411985-1A 2003-07-16 2004-07-12 tratamento da disfunção sexual BRPI0411985A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0316673A GB0316673D0 (en) 2003-07-16 2003-07-16 Treatment of female sexual dysfunction
GB0318095A GB0318095D0 (en) 2003-08-01 2003-08-01 Treatment of sexual dysfunction
GB0321308A GB0321308D0 (en) 2003-09-11 2003-09-11 Treatment of sexual dysfunction
PCT/IB2004/002286 WO2005007166A1 (en) 2003-07-16 2004-07-12 Treatment of sexual dysfunction

Publications (1)

Publication Number Publication Date
BRPI0411985A true BRPI0411985A (pt) 2006-08-29

Family

ID=34084177

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411985-1A BRPI0411985A (pt) 2003-07-16 2004-07-12 tratamento da disfunção sexual

Country Status (7)

Country Link
EP (1) EP1653966A1 (pt)
JP (1) JP2007516949A (pt)
BR (1) BRPI0411985A (pt)
CA (1) CA2532252A1 (pt)
MX (1) MXPA06000623A (pt)
TW (1) TW200505410A (pt)
WO (1) WO2005007166A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
AR048128A1 (es) * 2003-12-01 2006-04-05 Akzo Nobel Nv Un tratamiento de la difuncion sexual
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
NZ551340A (en) * 2004-04-22 2010-10-29 Boehringer Ingelheim Int Pharmaceutical composition comprising flibanserin and a melanocortin agonist for the treatment of premenstrual disorder or sexual aversion disorder
HRP20130892T1 (hr) 2004-05-11 2013-11-08 Emotional Brain B.V. Farmaceutske formulacije i njihove upotrebe u lijeäśenju ženske seksualne disfunkcije
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
WO2008117269A2 (en) 2007-03-28 2008-10-02 Atir Holding S.A. Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof
PE20080090A1 (es) * 2006-05-09 2008-03-14 Boehringer Ingelheim Int Flibanserina para el tratamiento de trastornos post-menopausicos del deseo sexual
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
AU2007286288A1 (en) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CN104721168A (zh) 2006-08-25 2015-06-24 贝林格尔·英格海姆国际有限公司 控制释放系统及其制造方法
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
EP2695932A1 (en) 2012-08-08 2014-02-12 Ab Nanol Technologies Oy Grease composition
EP3833341B1 (en) * 2018-08-07 2025-04-02 Ilylt, LLC Compositions for use in treating sexual dysfunction and non therapeutic methods for enhancing sexual response and pleasure
AU2020377914A1 (en) * 2019-11-08 2022-06-02 Vella Bioscience, Inc. Peripherally acting cannabidiol(CBD)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders
WO2024173493A1 (en) * 2023-02-14 2024-08-22 Daré Bioscience, Inc. Compositions and methods of treating female sexual dysfunction and female sexual arousal disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055070A1 (en) * 1999-07-01 2003-03-20 Wilma Harrison Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
US20020052370A1 (en) * 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
GB0105893D0 (en) * 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
GB0106446D0 (en) * 2001-03-15 2001-05-02 Vernalis Res Ltd Chemical compounds
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
TW200505410A (en) 2005-02-16
CA2532252A1 (en) 2005-01-27
WO2005007166A1 (en) 2005-01-27
JP2007516949A (ja) 2007-06-28
MXPA06000623A (es) 2006-04-11
EP1653966A1 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
BRPI0411985A (pt) tratamento da disfunção sexual
EA200801551A1 (ru) Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
NO20085099L (no) Puritonderivativer som HM74A agonister
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
PH12014501440A1 (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
CL2009000576A1 (es) Un compuesto {1-etilsulfonil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo o su sal; inhibidor de jak; composicion farmaceutica; y su uso para tratar artritis reumatoide.
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
CY1118007T1 (el) Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
CY1112067T1 (el) Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
PE20150680A1 (es) Variantes de polipeptidos receptores de activina iib y aplicaciones de estos
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
HN2005036256A (es) Derivados fusionados de pirazol y metodos de tratamiento de trastornos metabolicos con estos
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
MA32349B1 (fr) Antagonistes de la voie hedgehog a base de phtalazines disubstituees
UY3512Q (es) Plancha para el cabello
CL2008001074A1 (es) Uso de compuestos de triazol, antagonistas de smo para tratar cancer.
MX2010001357A (es) Broche unitario para cabello y metodo de uso.
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
ECSP045021A (es) Terapia de combinacion para el tratamiento del cancer

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.